Study Using Nanogen Assay Confirms NT-proBNP to Have Utility as Predictor of Mortality in Patients With Severe Congestive Heart Failure

Jun 08, 2005, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN)
 today announced that a study published in the European Journal of Heart
 Failure concluded that for patients with severe congestive heart failure, a
 significantly higher risk of one-year mortality was associated with elevated
 levels of N-terminal brain natriuretic peptide (NT-proBNP).  NT-proBNP is the
 protein marker Nanogen is utilizing to develop a point-of-care test to predict
 congestive heart failure.  The published study looked at N-terminal atrial
 natriuretic peptide (NT-proANP), brain natriuretic peptide (BNP) and NT-proBNP
 and found all to be significant individual predictors of one-year mortality.
 The study was co-authored by Dr. Eric Stanton, associate professor of
 medicine, McMaster University and consultant to Nanogen's subsidiary SynX, and
 Dr. Peter Kupchak, director of biometry and clinical operations at SynX, and
     The study also showed that the risk of mortality from congestive heart
 failure can be more accurately ascertained if levels of NT-proBNP are known,
 even after accounting for other important clinical variables such as the
 severity of heart failure.  Attributes of NT-proBNP, including a longer
 half-life and higher plasma concentration, can provide benefits as a
 point-of-care diagnostic in comparison to a test measuring the peptide BNP.
 These benefits could include accuracy, sensitivity and ease-of-use of the
 product in a clinical setting.
     "This is one of the first peer-reviewed studies to validate the utility of
 Nanogen's NT-proBNP assay as a significant predictor of mortality in a chronic
 congestive heart failure population, as well as one of the first studies
 published that compares the three most important markers associated with the
 disease," said Dr. Stanton.
     "This study validates the importance of using the single marker NT-proBNP
 to predict congestive heart failure.  By developing a point-of-care diagnostic
 utilizing this marker, Nanogen takes another step forward in its mission to
 bring to market diagnostic tools that improve the accessibility and quality of
 information available to healthcare providers so that they can select the
 appropriate course of therapy and potentially extend the lives of patients,"
 said Howard C. Birndorf, Nanogen's chairman of the board and CEO.
     Natriuretic peptides have been validated as sensitive and specific markers
 of left ventricular dysfunction, and have been associated with heart failure,
 but there is very little comparative data on these markers in predicting
 survival in advanced heart failure.  The article, titled "A direct comparison
 of the natriuretic peptides and their relationship to survival in chronic
 heart failure of a presumed non-ischaemic origin" in Volume 7 Issue 4 (June)
 of the journal, presents data from a study of evaluated plasma levels of three
 peptides, BNP, NT-proANP and NT-proBNP, in 153 subjects.  The study concluded
 that the three natriuretic peptides were significant individual predictors of
 mortality within one year in patients with chronic heart failure.
     About Nanogen, Inc.
     Nanogen's advanced diagnostics provide researchers, clinicians, physicians
 and patients worldwide with improved methods and tests that can predict,
 diagnose and ultimately help treat disease.  Nanogen's products include
 real-time PCR reagents, the NanoChip(R) Molecular Biology Workstation platform
 for molecular diagnostic applications and the Nexus Dx(TM) line of
 point-of-care diagnostic tests for cardiac related health conditions.
 Nanogen's ten years of pioneering research involving nanotechnology may also
 have future applications in medical diagnostics, biowarfare and other
 industries.  For additional information please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.